STOCK Cdkn2atm2.1Rdp Tg(Cnp-TVA,-lacZ)B8Ubc/Kctt

Status

Available to order

EMMA IDEM:04995
Citation informationRRID:IMSR_EM:04995 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameSTOCK Cdkn2atm2.1Rdp Tg(Cnp-TVA,-lacZ)B8Ubc/Kctt
Alternative nameCtv-a INK4a-/-
Strain typeTransgenic Strains
Allele/Transgene symbolTg(Cnp-TVA,-lacZ)B8Ubc, Cdkn2atm2.1Rdp
Gene/Transgene symbolTg(Cnp-TVA,-lacZ)B8Ubc, Cdkn2a

Information from provider

ProviderLene Uhrbom
Provider affiliationDepartment of Neuroscience, Uppsala University
Additional ownerLene Uhrbom, Uppsala University, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden
Genetic informationTransgenic construct: pCNPase-TV-A-IRES-lacZ made in FVB/N. Crossed with strain containing targeted deletion p16INK4a (exon 1a of the cyclin-dependent kinase inhibitor 2A gene).
Phenotypic informationAllows for infection of 2',3'-cyclic nucleotide 3' phosphodiesterase (CNPase)-expressing cells by RCAS virus. The deletion of exon 1a in the cyclin-dependent kinase inhibitor 2A gene results in complete loss of p16INK4a transcription but not p19ARF.
Breeding historyThe TV-A founder mouse was crossed with FVB/N and subsequently intercrossed to establish homozygotes. Following, TVA-A transgenic mice were crossed with p16INK4a null mice and subsequently F1 progeny were crossed to generate mice homozygous for TV-A and p16INK4a deletion.
References
  • Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma.;Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L, ;2009;Oncogene;28;2266-75; 19421151
  • Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.;Sharpless N E, Bardeesy N, Lee K H, Carrasco D, Castrillon D H, Aguirre A J, Wu E A, Horner J W, DePinho R A, ;2001;Nature;413;86-91; 11544531
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreKarolinska Institutet, Stockholm, Sweden
Animals used for archivingheterozygous males, wild-type FVB/N females
Breeding at archiving centreNo breeding at Karolinska Inst.
Stage of embryos2-cell

Disease and phenotype information

IMPC phenotypes (gene matching)
  • cataract / IMPC
  • abnormal lens morphology / IMPC
  • developmental and structural abnormality / IMPC
  • abnormal eye morphology / IMPC
  • cyst / IMPC
  • process of degenerative change / IMPC
MGI phenotypes (allele matching)
  • increased tumor incidence / MGI
  • thymus hyperplasia / MGI
  • increased sarcoma incidence / MGI
  • increased osteosarcoma incidence / MGI
  • increased incidence of tumors by chemical induction / MGI
  • increased thymus weight / MGI
  • increased double-positive T cell number / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • increased CD8-positive, alpha-beta T cell number / MGI
  • increased small lymphocytic lymphoma incidence / MGI
  • increased splenocyte proliferation / MGI
  • increased lymphoma incidence / MGI
MGI phenotypes (gene matching)
  • extramedullary hematopoiesis / MGI
  • abnormal spleen morphology / MGI
  • thymus hyperplasia / MGI
  • hindlimb paralysis / MGI
  • abnormal retinal photoreceptor morphology / MGI
  • increased metastatic potential / MGI
  • microphthalmia / MGI
  • abnormal lens morphology / MGI
  • cataract / MGI
  • abnormal retina morphology / MGI
  • male infertility / MGI
  • blindness / MGI
  • neoplasm / MGI
  • increased papilloma incidence / MGI
  • abnormal tumor incidence / MGI
  • increased tumor incidence / MGI
  • increased B cell derived lymphoma incidence / MGI
  • increased T cell derived lymphoma incidence / MGI
  • increased sarcoma incidence / MGI
  • increased fibrohistocytoma incidence / MGI
  • increased carcinoma incidence / MGI
  • seizures / MGI
  • premature death / MGI
  • abnormal eye morphology / MGI
  • abnormal spleen red pulp morphology / MGI
  • abnormal sperm number / MGI
  • oligozoospermia / MGI
  • no phenotypic analysis / MGI
  • abnormal cell cycle / MGI
  • retinal detachment / MGI
  • testicular atrophy / MGI
  • abnormal lens capsule morphology / MGI
  • abnormal keratinocyte physiology / MGI
  • increased hemangiosarcoma incidence / MGI
  • increased tumor growth/size / MGI
  • abnormal retinal inner nuclear layer morphology / MGI
  • increased osteosarcoma incidence / MGI
  • increased squamous cell carcinoma incidence / MGI
  • increased incidence of tumors by chemical induction / MGI
  • increased incidence of tumors by ionizing radiation induction / MGI
  • decreased incidence of tumors by chemical induction / MGI
  • increased testis weight / MGI
  • decreased testis weight / MGI
  • increased thymus weight / MGI
  • increased double-positive T cell number / MGI
  • abnormal posterior eye segment morphology / MGI
  • abnormal retinal ganglion layer morphology / MGI
  • reproductive system phenotype / MGI
  • vision/eye phenotype / MGI
  • abnormal skin physiology / MGI
  • abnormal lens development / MGI
  • abnormal cell physiology / MGI
  • abnormal retinal neuronal layer morphology / MGI
  • binocular blindness / MGI
  • abnormal spermatocyte morphology / MGI
  • delayed cellular replicative senescence / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • increased CD8-positive, alpha-beta T cell number / MGI
  • increased spleen white pulp amount / MGI
  • increased lung carcinoma incidence / MGI
  • increased brain tumor incidence / MGI
  • increased small lymphocytic lymphoma incidence / MGI
  • increased histiocytic sarcoma incidence / MGI
  • increased splenocyte proliferation / MGI
  • increased gastrointestinal stromal tumor incidence / MGI
  • primary vitreous hyperplasia / MGI
  • increased melanoma incidence / MGI
  • increased cutaneous melanoma incidence / MGI
  • increased acute lymphoblastic leukemia incidence / MGI
  • increased fibrosarcoma incidence / MGI
  • persistent hyperplastic primary vitreous / MGI
  • increased fibroblast proliferation / MGI
  • increased lymphoma incidence / MGI

Literature references

  • Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma.;Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L, ;2009;Oncogene;28;2266-75; 19421151
  • Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.;Sharpless N E, Bardeesy N, Lee K H, Carrasco D, Castrillon D H, Aguirre A J, Wu E A, Horner J W, DePinho R A, ;2001;Nature;413;86-91; 11544531

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).